July 15, 2022

FDA Approves Temporary Importation of Bracco Iomeprol Injection

Bracco Diagnostics Inc., (Bracco) in conjunction with the U.S. Food and Drug Administration (FDA) has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address iodinated contrast shortages. Access Bracco’s “Dear Healthcare Provider” letter for details.

For more information, contact Gloria Romanelli, American College of Radiology® Senior Director, Legislative and Regulatory Relations and Legal Counsel, Quality and Safety.